Stock Scorecard



Stock Summary for Akebia Therapeutics Inc (AKBA)

Total Score

11 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AKBA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AKBA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AKBA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for AKBA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Financial Details for AKBA

Company Overview

Company Name Akebia Therapeutics Inc
Country USA
Description Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2022
Next Earnings Date 2/27/2023

Stock Price History

Last Day Price 0.29
Last Day Volume 1,817,727
Average Daily Volume 1,266,847
52-Week High 2.93
52-Week Low 0.24
Last Price to 52 Week Low 20.83 %

Valuation Measures

Trailing PE 0.00
Industry PE 38.49
Sector PE 93.33
5-Year Average PE -1.76
Free Cash Flow Ratio 0.37
Industry Free Cash Flow Ratio 8.26
Sector Free Cash Flow Ratio 37.81
Book Value Per Share Most Recent Quarter 0.08
Price to Book Ratio 3.40
Industry Price to Book Ratio 6.06
Sector Price to Book Ratio 15.40
Price to Sales Ratio Twelve Trailing Months 0.18
Industry Price to Sales Ratio Twelve Trailing Months 67.23
Sector Price to Sales Ratio Twelve Trailing Months 25.28

Share Statistics

Total Shares Outstanding 183,962,000
Market Capitalization 53,348,980
Institutional Ownership 0.00 %

Dividends

Ex-Dividend Date
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00 %
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Average Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio 0.00 %

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth 26.24 %
Reported EPS Past Year -0.48
Reported EPS Prior Year -1.70
Net Income Twelve Trailing Months -155,688,000
Net Income Past Year -282,840,000
Net Income Prior Year -383,457,000
Quarterly Revenue Growth YOY 0.40 %
5-Year Revenue Growth 4.66 %

Balance Sheet

Total Cash Per Share 0.79
Total Cash Most Recent Quarter 144,761,000
Total Cash Past Year 149,800,000
Total Cash Prior Year 268,690,000
Net Cash Position Most Recent Quarter 78,814,000
Net Cash Position Past Year 52,257,000
Long Term Debt Past Year 97,543,000
Long Term Debt Prior Year 96,378,000
Total Debt Most Recent Quarter 65,947,000
Equity to Debt Ratio Past Year 0.44
Equity to Debt Ratio Most Recent Quarter 0.17
Current Ratio Most Recent Quarter 1.26
Total Stockholder Equity Past Year 76,456,000
Total Stockholder Equity Prior Year 247,618,000
Total Stockholder Equity Most Recent Quarter 13,853,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

MACD -0.01
MACD Signal -0.01
20-Day Bollinger Lower Band 1.47
20-Day Bollinger Middle Band 2.01
20-Day Bollinger Upper Band 2.54
Beta 1.33
RSI 50.50
50-Day SMA 0.93
200-Day SMA 4.22

System

Modified 12/2/2022 10:55:11 PM